Speech-Language Pathologists in Attica, OH Accepting Medicare
2 Speech-Language Pathologists found. Showing 1 - 2
 Katlyn Ilene Dutko Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 13343 E Us Highway 224, Attica, OH 44807 Phone: 419-426-3344 |
Mrs. Denise Kummerer Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 13343 E Us Highway 224, Attica, OH 44807 Phone: 419-426-3344 |
News Archive
Predicting better immunotherapy response, neurological outcomes in adults with autoimmune cerebellar ataxia
While autoimmune cerebellar ataxia (a loss of muscle control coordination) can lead to severe disability with some patients becoming wheelchair-bound, there are factors that may help predict better immunotherapy response, according to the Mayo Clinic study published by JAMA Neurology.
SXC prices previously announced public offering of common shares
SXC Health Solutions Corp. announced today the pricing of its previously announced public offering of common shares. Under the offering, SXC will sell 5,200,000 of its common shares at a price to the public of $90.60 per share.
Alvine Pharmaceuticals reports data of ALV003 in gastric simulation model at DDW 2010
Alvine Pharmaceuticals, Inc., today announced the reporting of scientific data on the performance of its lead compound, ALV003, in a gastric simulation model. The data were presented at the 2010 Digestive Disease Week (DDW) meeting held in New Orleans, Louisiana.
Artisan Pharma enrolls 750 patients in Phase 2b study of ART-123 in sepsis patients with DIC
Artisan Pharma, Inc., a private biopharmaceutical company dedicated to bringing best-in-class critical care therapeutics to patients, today announced the completion of patient enrollment in its Phase 2b study of ART-123 (Recomodulin® - recombinant human thrombomodulin) in sepsis patients with disseminated intravascular coagulation (DIC). The clinical trial was a randomized, double-blind, placebo-controlled Phase 2b study to assess the safety and efficacy of ART-123 in patients with sepsis and DIC.
Nanobusiness Alliance statement reflects effective environmental, health, and safety management of nanotechnology
The NanoBusiness Alliance today issued a Position Statement on Nanomaterials Product Sustainability, which reflects NanoBusiness Alliance members' enduring commitment to managing effectively the environmental, health, and safety (EHS) implications of nanotechnology.
› Verified 9 days ago